Fucoidan Does Not Exert Anti-Tumorigenic Effects on Uveal Melanoma Cell Lines by Dithmer, Michaela et al.
 Mar. Drugs 2017, 15, x; doi: FOR PEER REVIEW  www.mdpi.com/journal/marinedrugs 
Article 1 
Fucoidan does not exert anti-tumorigenic effects on 2 
uveal melanoma cell lines 3 
Michaela Dithmer1, Anna-Maria Kirsch1, Elisabeth Richert1, Sabine Fuchs2, Fanlu Wang2, Harald 4 
Schmidt3, Sarah E. Coupland4, Johann Roider1, Alexa Klettner1* 5 
1 University of Kiel, University Medical Center, Department of Ophthalmology, Arnold-Heller-Str. 3, Kiel, 6 
Germany 7 
2 University of Kiel, University Medical Center, Experimental Trauma Surgery, Arnold-Heller-Str. 3, Kiel, 8 
Germany 9 
3 MetaPhysiol, Am Römerberg, Essenheim, Germany 10 
4 Liverpool Ocular Oncology Research Group, Pathology, Dept. of Molecular and Clinical Cancer Medicine, 11 
University of Liverpool, Liverpool, United Kingdom 12 
*Corresponding author: Alexa Klettner, University of Kiel, University Medical Center, Department of 13 
Ophthalmology, Arnold-Heller-Str. 3, 24105 Kiel, Germany, Email: aklettner@auge.uni-kiel.de, Tel: 0049 14 
431 500 24283, Fax: 0049 431 5000 24244 15 
Abstract  16 
Background 17 
The polysaccharide Fucoidan is widely investigated as an anti-cancer agent. Here, we tested the 18 
effect of fucoidan on uveal melanoma cell lines.  19 
Methods 20 
The effect of 100 µM fucoidan was investigated on five cell lines (92.1, Mel270 OMM1, OMM2.3, 21 
OMM2.53) and of 1 µg/ml – 1 mg/ml in two cell lines (OMM1, OMM2.3). Cell proliferation and 22 
viability were investigated with a WST-1 assay, migration in a wound healing (scratch) assay. 23 
Vascular Endothelial Growth Factor (VEGF) was measured in ELISA. Angiogenesis was evaluated 24 
in co-cultures with endothelial cells. Cell toxicity was induced by hydrogen-peroxide. Protein 25 
expression (Akt, ERK1/2, Bcl-2, Bax) was investigated in Western blot.  26 
Results 27 
Fucoidan increased proliferation in two and reduced it in one cell line. Migration was reduced in 28 
three cell lines. The effect of fucoidan on VEGF was cell type and concentration 29 
dependentFuciodan did not change the secretion of VEGF. In endothelial co-culture with 92.1, 30 
fucoidan significantly increased tubular structures. Moreover, fucoidan significantly protected all 31 
tested uveal melanoma cell lines from hydrogen-peroxide induced cell death. Under oxidative 32 
stress, fFucoidan did not alter the expression of Bcl-2, Bax or ERK1/2, while inducing Akt 33 
expression in 92.1 cells but not in any other cell line.  34 
Conclusion 35 
Fucoidan did not show anti-tumorigenic effects but displayed protective and pro-angiogenic 36 
properties, rendering fucoidan unsuitable as a potential new drug for the treatment of uveal 37 
melanoma.  38 
Keywords: Fucoidan; uveal melanoma; VEGF; angiogenesis; oxidative stress 39 
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 40 
Introduction 41 
Uveal melanoma (UM) is the most common primary tumor of the adult eye with an incidence of 42 
4-8 per million in Western countries [1]. It arises from melanocytes of the uvea, the tissue between 43 
the inner retina and the outer scleral layer of the posterior eye, including the iris, ciliary body and 44 
choroid. Most UM arise from the choroid, which provides blood supply and maintenance for the 45 
photoreceptors of the retina. The disease generally occurs in the 6th decade of life and primarily 46 
affects fair-skinned people of Caucasian descent [2]. Treatment options for UM depend on the tumor 47 
size and patient choice, but include transpupillary thermotherapy, radiation therapy (including 48 
plaque brachytherapy, proton beam- and gamma-knife radiotherapy), local tumor resection and 49 
enucleation [2]. Radiation therapy is conducted with good success for medium sized tumors, 50 
however, may result in profound vision loss due to side effects [3]. Metastases develop in up to 50% 51 
of UM patients, primarily affecting the liver. The prognosis of these patients is poor, as the current 52 
treatment options for metastatic UM are very limited [1,4]. New treatment option for this disease is 53 
currently of great interest and activity of numerous basic and clinical research teams.  54 
A promising new approach in the treatment of cancer is the use of fucoidan, a sulfated 55 
polysaccharide, obtained from the cell-wall matrix of brown algae. Fucoidan contains high amounts 56 
of L-fucose, but has a highly complex structure and may differ substantially depending on different 57 
species, regional origin and even mode of extraction [5]. Fucoidan has been described in several 58 
studies to have anti-tumorigenic properties, e.g. it has been shown to be anti-proliferative and/or 59 
pro-apoptotic on several kind of tumors cells, such as colon cancer [6], hepatoma [7], urinary bladder 60 
cancer cells [8], breast cancer [9], melanoma cells [10] or prostate cancer cells [1011]. Fucoidan also 61 
has shown anti-angiogenic properties [6, 11,12, 13] and is discussed as a promising anti-cancer agent 62 
[1314]. Therefore, fucoidan might be an interesting new therapeutic compound for the treatment of 63 
UM. 64 
Important parameters in tumor progression are proliferation, migration and angiogenic 65 
potential [5]. We tested the effect of fucoidan on these parameters in five different UM cell lines. One 66 
of the factors that have been discussed to be involved in the pathogenesis of UM is Vascular 67 
Endothelial Growth Factor (VEGF). VEGF has been reported in UM, ocular fluid of UM patients and 68 
UM cell lines [1415-176]. A meta-analysis showed that VEGF expression in patients with UM was 69 
significantly higher compared to controls [1718]. Moreover, VEGF has been elevated in patients with 70 
metastatic UM [1617], and has been proposed to be a marker for high risk patients [187]. Fucoidan 71 
has been described to reduce VEGF expression in breast cancer cells [9] and in Lewis tumor bearing 72 
mice [198]. Therefore, we investigated the effect of fucoidan on VEGF secretion by UM cells.  73 
Oxidative stress is an important factor in tumor pathology and metastasis [19,20,21] and is 74 
utilized by therapeutic compounds to destroy the tumor tissue [2122]. In primary UM, the tumor is 75 
treated with ionizing radiation, which induces cell death via oxidative stress-mediated killing of 76 
tumor cells [3,2223]. Therefore, we also tested the effect of fucoidan on UM cells stressed with 77 
Hydrogen peroxide (H2O2). Fucoidan has been shown to exert its anti-tumor functions via ERK1/2, 78 
Akt [6, 10,11,12], Bcl-2 and Bax [8,9, 23,24,25]; all these proteins have also been implicated in the 79 
pathogenesis of UM [25-30]. Therefore, we also assessed how fucoidan affect the expression of these 80 
proteins under oxidative stress. 81 
 82 
Results 83 
Proliferation 84 
Fucoidan had a cell specific effect on cell proliferation. In 92.1 cells, fucoidan induced a 85 
significant increase in cell number after all one day (p < 0.05), two days (p < 0.01) and three days (p < 86 
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0.05) after incubation, while in Mel270 cells, fucoidan reduced proliferation after two and three days 87 
(both p < 0.05). OMM1 and OMM2.3 were not affected by fucoidan, while in OMM2.5 cells, fucoidan 88 
increased cell number significantly after one day of incubation (p < 0.001) (figure 1). In addition, for 89 
OMM1 and OMM2.3, different concentrations (1 µg/ml, 10 µg/ml, 100 µg/ml 1 mg/ml) after 1 day of 90 
incubation were tested. Fucoidan did not show any significant effect in either cell line and either 91 
concentration (figure 2). 92 
 93 
 94 
Figure 1: Proliferation (time line). Proliferation of uveal melanoma cells was tested after incubation 95 
with fucoidan (100 µg/ml) for one, two, and three days in A) 92.1, B) Mel 270, C) OMM1, D) OMM2.3 96 
and E) OMM2.5 cells. Fucoidan exhibited a cell specific effect with an acceleration of proliferation in 97 
92.1 and OMM2.5 cells, but a decrease in Mel270 cells. Statistical significance was evaluated with 98 
student’s t-test. + p < 0.05 compared to control, ++ p < 0.01 compared to control, +++ p < 0.001 99 
compared to control. Co: control. 100 
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101 
Figure 2. Proliferation (concentration). Proliferation of uveal melanoma cell lines (A) OMM1 and (B) 102 
OMM2.3 was tested after 1 day of treatment with 1µg/ml, 10 µg/ml, 100 µg/ml or 1000 µg/ml. No 103 
significant effect on proliferation was found. Statistical significance was evaluated with student’s 104 
t-test. 105 
 106 
Wound healing/Migration 107 
Fucoidan induced a significant decrease in wound healing ability in 92.1 cells, OMM2.3, and 108 
OMM2.5 cells (all p < 0.05). No significant effect was seen on Mel270 and OMM1 cells (figure 23).  109 
 110 
 111 
Figure 23: Wound healing. Wound healing ability of uveal melanoma cells was tested after 112 
incubation with fucoidan (100 µg/ml) for one day in 92.1, Mel 270, OMM1, OMM2.3 and OMM2.5 113 
cells. Fucoidan significantly decreased wound healing in 92.1, OMM2.3 and OMM2.5 cells. Statistical 114 
significance was evaluated with student’s t-test. + p < 0.05 compared to control. Co = control, fuco= 115 
fucoidan. 116 
VEGF Secretion 117 
We have previously shown that all tested UM cell lines secrete VEGF [3132] and that this batch 118 
of fucoidan reduces VEGF in retinal pigment epithelial cells in the tested concentration [33]. 119 
Fucoidan (100 µg/ml) did not inhibit VEGF secretion in any of the UM cell lines when incubated for 120 
up to three days (figure 34). However, these results are dose and cell-line dependent. In a separate 121 
set of experiments, we investigated different concentrations of fucoidan (1 µg/ml, 10 µg/ml, 100 122 
µg/ml 1 mg/ml) in OMM1 and OMM2.3 cells after treatment for 1 day. While for OMM2.3 cells, a 123 
slight but significant induction of VEGF could be found at 10 and 100 µg/ml, fucoidan at 1 mg/ml 124 
significantly reduced VEGF in OMM1 cells (figure 5). 125 
Formatiert: Schriftart: 9 Pt.
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 126 
Figure 34: VEGF secretion (time line). Influence of fucoidan (100 µg/ml) on VEGF secretion by uveal 127 
melanoma cell lines. Treatment with fucoidan for up to three days did not show any significant 128 
influence on the secretion of VEGF in any of the cell lines tested (A) 92.1, (B) Mel270, (C) OMM1, (D) 129 
OMM2.3, (E) OMM2.5). The secretion of VEGF was determined in VEGF VEGF-ELISA. Statistical 130 
significance was evaluated with student’s t-test. Co: control. 131 
 132 
 133 
Figure 5: VEGF secretion (concentration). Influence of different concentrations of fucoidan (1 µg/ml 134 
– 1 mg/ml) on VEGF secretion in (A) OMM1 and (B) OMM2.3 uveal melanoma cell lines. Treatment 135 
with fucoidan displayed a dose- and cell-dependent effect with significant reduction of VEGF in 136 
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OMM1 (100 µg/ml, 1 mg/ml) and a slight but significant induction in OMM2.3 cells (10 µg/ml, 100 137 
µg/ml). The secretion of VEGF was determined in VEGF-ELISA. Statistical significance was 138 
evaluated with student’s t-test. + p < 0.05, ++ p < 0.01, +++ p < 0.001. Co: control. 139 
Angiogenesis 140 
Fucoidan induced an elevation of the tubular area in a co-culture of endothelial cells with 92.1 141 
cells (p < 0.01). Similarly, fucoidan increased tubular length (p < 0.01). Fucoidan did not, however, 142 
influence the total area of endothelial coverage in these co-cultures. No effect was seen in co-cultures 143 
of endothelial cells with the metastatic UM cell line OMM2.3 (figure 46).   144 
 145 
Figure 46: Tubular structures in endothelial – uveal melanoma cell line co-culture. Uveal melanoma 146 
cell line 92.1 and OMM2.3 were co-cultured with outgrowth endothelial cells and subjected to 100 147 
µg/ml fucoidan. In co-cultures with endothelial cells and 92.1 cell line (A), tubular area and tubular 148 
length were increased by fucoidan. Total coverage with endothelial cells, however, was not 149 
influenced. In co-cultures with endothelial cells and OMM2.3 cell line, fucoidan displayed no effect 150 
(B).  Statistical significance was evaluated with student’s t-test.  ++ p < 0.01 compared to control. Co 151 
= control, fuco = fucoidan. 152 
Protection 153 
We have previously shown that the UM cell lines have a different susceptibility towards 154 
H2O2-induced cell toxicity [3132]. In all cell lines tested, fucoidan exerted a significant protection on 155 
UM cell lines under oxidative stress. (92.1, 250 µM H2O2, p < 0.01; Mel270, 500 µM H2O2, p < 0.01; 156 
OMM1, 500 µM H2O2, p < 0.05; OMM2.3, 1000 µM H2O2, p < 0.001; OMM2.5, 1000 µM H2O2, p < 157 
0.001) (figure 57). 158 
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 159 
Figure 75: Cell viability of uveal melanoma cell lines under oxidative stress. Uveal melanoma cell 160 
lines 92.1, Mel270, OMM1, OMM2.3, and OMM2.5 were subjected to 250 µM (92.1), 500 µM, (Mel270 161 
and OMM1) or 1000 µM (OMM2.3 and OMM2.5) H2O2. The toxicity of these concentrations of H2O2 162 
in the respective cell line has been shown previously [321]. The ability of 100 µg/ml fucoidan to 163 
protect cell viability after H2O2 treatment was detected in WST assay. All tested substances exhibited 164 
statistically significant protection in all cell lines tested. Statistical significance was evaluated with 165 
student’s t-test. + p < 0.05, ++ p < 0.01, +++ p < 0.001. 166 
 167 
Figure 86: Expression of Bcl-2 and Bax. Uveal melanoma cell lines (A) 92.1, (B) Mel270, (C) OMM1, 168 
(D) OMM2.3, (E) OMM2.5 were subjected to (A) 250 µM, (B, C) 500 µM or (D, E) 1000 µM H2O2. The 169 
effect of 100 µg/ml fucoidan on the expression of Bcl-2 and Bax was investigated in Western blot. 170 
Example blots (compound) and densitometric evaluations are shown. Statistical significance was 171 
evaluated with student’s t-test.  172 
Protein expression  173 
Under oxidative stress conditions Fucoidan fucoidan did not show any influence on Bcl-2 or 174 
Bax expression in any of the cell lines (figure 68). In 92.1 cell lines, fucoidan induced a significant 175 
induction of Akt expression compared to cells treated with H2O2 alone, while it showed no 176 
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significant effect on the other cell lines (figure 79). Considering ERK1/2, no statistically significant 177 
change in ERK1/2 expression or phosphorylation compared to H2O2-treated cells can be found 178 
(figure 810).  179 
 180 
Figure 79: Expression of Akt. Uveal melanoma cell lines 92.1, Mel270, OMM1, OMM2.3 and OMM2.5 181 
were subjected to 250 µM (92.1), 500 µM (Mel270 and OMM1) or 1000 µM  (OMM2.3 and OMM2.5) 182 
H2O2. The effect 100 µg/ml fucoidan on the expression of Akt was investigated in Western blot. 183 
Densitometric evaluations (A) and example blots (compound) (B) are shown. Statistical significance 184 
was evaluated with student’s t-test. + p < 0.05. 185 
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 186 
Figure 810: Expression and phosphorylation of ERK1/2. Uveal melanoma cell lines 92.1, Mel270, 187 
OMM1, OMM2.3 and OMM2.5 were subjected to 250 µM (92.1), 500 µM (Mel270 and OMM1) or 1000 188 
µM (OMM2.3 and OMM2.5) H2O2. The effect of 100 µg/ml fucoidan on the expression and 189 
phosphorylation of ERK1/2 was investigated in Western blot. Densitometric evaluation of (A) ERK 190 
and (B) pERK blots are shown for the 42 kDa isoform. (C) Example blots (compound). Statistical 191 
significance was evaluated with student’s t-test.  192 
Discussion 193 
Fucoidan has been shown to display a variety of anti-tumor effects on several types of tumors 194 
or cancer cell lines. Here, we investigated its effect on UM, a primary malignant neoplasm of the eye. 195 
We investigated classical parameters, such as proliferation, migration, VEGF secretion and 196 
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angiogenesis and additionally investigated the effect of fucoidan on H2O2-induced cell death and 197 
protein expression.  198 
Anti-proliferative activity of fucoidan has been shown for several cancer cell types, such as 199 
bronchopulmonary carcinoma [342], cutaneous melanoma cells [10,353], bladder cancer cells [8], 200 
breast cancer cells [9], or B-cell lymphoma [364]. In our study, fucoidan reduced proliferation in one 201 
cell line (Mel 270), but, surprisingly, it induced proliferation in two cell lines (92.1 and OMM2.5). In 202 
OMM1 and OMM2.3 cells, both time line (100 µg/ml) and concentration (1 µg/ml – 1 mg/ml) was 203 
tested and no effect on proliferation was seen at either time point or contranction. The effect 204 
therefore is clearly cell type specific. Moreover, the pro-proliferative effect on two cell lines would be 205 
a worrisome result if fucoidan were to be used in UM patients.  206 
Fucoidan decreased its wound healing ability in three (92.1; OMM2.3; OMM2.5) out of five UM 207 
cell lines. This indicates that fucoidan interferes with migration in these cell lines, especially as 208 
wound healing assay measure both proliferation and migration, and we found fucoidan to induce 209 
proliferation in 92.1 and OMM2.5 cells. Fucoidan has been shown to inhibit migration e.g. in colon, 210 
lung or bladder cancer cells [6,375,3638]. Again, the effect is cell-type dependent, and no general 211 
anti-migratory effect of fucoidan could be shown here. 212 
When we tested the ability of fucoidan to reduce the availability of VEGF, no reduction of VEGF 213 
could be seen at a concentration of 100 µg/ml. This is in contrast to our findings in retinal pigment 214 
epithelial (RPE) cells [337] where we could find a significant reduction of detectable VEGF at this 215 
concentration using the same batch of fucoidan, and A similar reductive effect of VEGF expression 216 
by fucoidan has been shown for breast cancer cells [9]. It is of interest to note that the lack of effect on 217 
VEGF by fucoidan in this system cannot be solely due to the molecular properties of the fucoidan, as 218 
the exact same fucoidan has been shown to reduce VEGF secretion interactions in RPE cells [37]. 219 
Therefore, the effect of fucoidan is not only determined by the molecular structure of the fucoidan 220 
[5], but also by the target cells. As higher concentrations of fucoidan did reduce VEGF in OMM1 221 
cells, possibly the concentration chosen in this experiments were too low to exert an effect. However, 222 
even in higher concentrations, the effect was cell type dependent, as OMM2.3 did not show any 223 
reduction of VEGF in any of the fucoidan concentrations tested. The pathways of fucoidan-mediated 224 
VEGF reduction have not been elucidated to date, but it has been shown that fucoidan can inhibit the 225 
activation of VEGFR-2 by preventing the binding of VEGF165 to its receptor [3839]. We have 226 
previously shown that VEGF is autoregulated via the VEGFR-2 in RPE cells [3940], and so we 227 
hypothesized that the downregulation of VEGF was mediated by interfering with the 228 
autoregulatory pathway. The cell dependent effectinability of fucoidan to reduceconcerning VEGF 229 
in the UM cells may therefore be related to the presence of due to the lack of an autoregulatory 230 
pathway of VEGF expression in the tested melanoma cells.  231 
In addition, in our angiogenesis assay, fucoidan induced the outgrowth of tubular structures, 232 
both in length and area, in 92.1 cells. Even though the general interaction between 92.1 and 233 
endothelial cells were low, this result may indicate that fucoidan may facilitates angiogenesis 234 
primary UM, which would not be desirable in patient treatment. Again, this cannot simply be 235 
explained by the molecular structure of this particular fucoidan, as we have shown before that this 236 
exact fucoidan reduced angiogenic structures in RPE-endothelial cells co-cultures [3733].  237 
Fucoidan displayed a significant protective effect against H2O2-induced cell death in all tested 238 
cell lines. Fucoidan has been described to protect cells against oxidative stress [40,41,42]; however, to 239 
the best of our knowledge, this has not been shown in cancer cells before. Indeed, fucoidan when 240 
given in addition with a chemotherapeutic has been shown to increase oxidative stress in breast 241 
cancer cell [4243]. Antioxidants may enhance tumor progression [1920] and oxidative stress may 242 
protect from metastasis [2021], so the protection of cancer cells against oxidative stress by fucoidan 243 
has to be taken into consideration when discussing fucoidan-derived drugs as possible new cancer 244 
agents [1314]. Our data showed that the protective effects of fucoidan are not mediated via a change 245 
in the Bcl-2/Bax expression, or via the ERK1/2 or Akt pathway. Further research needs to be 246 
conducted in order to decipher the protective pathways of these compounds. 247 
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Fucoidan is also under investigation to be used in combination with other chemotherapeutic 248 
drugs in order to enhance their efficacy, as seen in e.g. melanoma [44] or breast cancer cells [43], 249 
where pro-apoptotic or anti-proliferative effects of the chemotherapeutics are enhanced by fucoidan. 250 
The results found in our study cannot extrapolated towards combination treatments, however, also 251 
in combination treatments, the effect of fucoidan is cell type dependent and may reduce the efficacy 252 
of the chemotherapeutic compound [45]. Moreover, it has been suggested that the 253 
apoptosis-enhancing effects of combination therapies combining fucoidan and chemotherapy is 254 
mediated by oxidative stress-enhancement by fucoidan [43], while our data show that fucoidan 255 
protects against oxidative stress. Therefore, our data cannot give a prediction about potential 256 
combination therapies in UM, but would strongly advice for caution. 257 
Conclusion 258 
The data obtained in this study strongly indicates that fucoidan is not suitable as a potential 259 
treatment for UM. 260 
Material and Methods 261 
Cell culture of melanoma cells 262 
Five established human UM cell lines were used. The cell lines 92.1 [4346] and Mel270 [474] 263 
originated from primary UM, while all OMM cell lines are of metastatic origin; OMM2.5 and 264 
OMM2.3 from liver metastases [4447] and OMM1 from a sub-cutaneous metastasis [4548]. Cell 265 
cultures were maintained in RPMI (PAA Laboratories, Cölbe, Germany), supplemented with 10% 266 
fetal calf serum (FCS) (Linaris, Dossenheim, Germany) and 1% penicillin/streptomycin (PAA). 267 
Medium was exchanged three times a week and cells were passaged after reaching confluence 268 
Fucoidan 269 
For the experiments, fucoidan from Sigma Aldrich (from Fucus vesiculosus, Sigma Aldrich, 270 
Steinheim, Germany; #F5631, [O28K3779; CAS 9072-19-9]) was used.  271 
Proliferation 272 
To determine the influence of fucoidan on proliferation, a defined number (200,000 cells) of the 273 
respective cell line was seeded on 12 well plates. Cells were stimulated with 100 µg/ml fucoidan (F. 274 
vesiculosus, Sigma Aldrich, Steinheim, Germany) for up to three days for one day, respectively. In 275 
addition, for the cell lines OMM1 and OMM2.3, a dose-response curve after 24 hours of incubation 276 
was determined, investigating 1 µg/ml, 10 µg/ml, 100 µg/ml and 1 mg/ml fucoidan. After the 277 
indicated period of time, a WST- assay was conducted.  278 
WST-assay 279 
Treated cells as described above were treated with WST-1 reagent (Hoffmann-La Roche, Basel, 280 
Switzerland) for 4 hours at 37°. The cells were rocked on a shaker for 2 min, the supernatant was 281 
collected, and measured at 450 nm. 282 
Scratch Assay 283 
The scratch assay was conducted as previously described with modifications [3733]. In brief, 284 
the respective cell line was seeded in a 12-well-plate. Two wounds were scratched in the confluent 285 
cell layer with a pipette tip and the cells were washed with PBS to remove detached cells. 286 
Microscopic bright field pictures of three spots were taken (AxioCam, Zeiss, Jena, Germany). 287 
Fucoidan (100 µg/ml) was added to the wells. After 90% wound closure of the control, another 288 
picture was taken. To analyse the wound healing capability of the cells, application was conducted 289 
in duplicates and three pictures per well were taken. The gap size of the wound was measured with 290 
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AxioVision Rel.4.8. (Zeiss, Jena, Germany), and the percentage of coverage of the wound was 291 
evaluated. Complete coverage was defined as 100%.  292 
VEGF- ELISA 293 
The supernatant of cell cultures was collected after 100 µM fucoidan incubation for up to three 294 
days. In addition, for the cell lines OMM1 and OMM2.3, a dose-response curve after 24 hours of 295 
incubation was determined, investigating 1 µg/ml, 10 µg/ml, 100 µg/ml and 1 mg/ml fucoidan.  and 296 
VEGF-content was measured by VEGF- ELISA (R&D Systems, Wiesbaden, Germany), following the 297 
manufacturer’s instructions. The range of detection of the ELISA was between 15 pg/ml and 1046 298 
pg/ml. The amount of VEGF secreted was normalized to cell number. Cell number was assessed 299 
with a trypan blue exclusion assay.  300 
Angiogenesis Assay 301 
Angiogenesis was evaluated in a direct co-culture system of UM cells and outgrowth 302 
endothelial cells.  303 
The isolation of outgrowth endothelial cells from peripheral blood was conducted as described 304 
previously [46,4749,50]. In brief, these cells were isolated from buffy coats by isolation of blood 305 
mononuclear cells. Mononuclear cells were seeded onto collagen coated 24-well plates in a density 306 
of 5 x 106 cells/well in EGM-2 (Lonza, Basel, Switzerland) with full supplements from the kit, 5% 307 
FCS, and 1% penicillin/streptomycin. After one week, adherent cells were collected by trypsin and 308 
reseeded on collagen coated 24-well plates in a density of 0.6 x 106 cells/well. After 2-3 weeks, 309 
colonies of endothelial cells (OEC) were harvested and further expanded over several passages 310 
using EGM-2 in a splitting ratio of 1:2. 311 
 Co-culture assays were performed for one primary (92.1) and one metastatic (OMM2.3) 312 
melanoma cell line. For co-cultures 100,000 cells/cm2 were seeded into fibronectin coated thermanox 313 
coverslips in 24 well plates in their respective cell culture medium. On the next day outgrowth 314 
endothelial cells (OEC) were added to the cultures in a density of 100,000 cells/ cm2 to the respective 315 
uveal melanoma cell line and co-cultures were further maintained for 7 days in EGM-2 treated with 316 
100 µg/ml fucoidan, respectively, or left untreated in control groups. After 7 days co-cultures were 317 
fixed with 4% paraformaldehyde and outgrowth endothelial cells were immunostained for the 318 
endothelial marker CD31. All cells are counterstained by Hoechst and pictures were taken with a 319 
confocal laser scanning microscope (Zeiss LSM 510 Meta, Jena, Germany). Angiogenesis was 320 
evaluated in comparison to untreated controls. For each group, at least 3 pictures were taken from 321 
two technical replicates. These experiments and the picture analysis were performed with 322 
endothelial cells from three different donors. 323 
Image Analysis 324 
The microscopic images were analyzed using the image processing program ImageJ Vers. 1.47 325 
and GIMP 2.8. The analysis of angiogenic structures was conducted as previously described [4851]. 326 
In brief, tube-like structures were extracted from the background by automatic segmentation after 327 
background correction. The binaries of the tube-like structures were further processed, including a 328 
final manual correction. The resulting binaries were analyzed for the area and the length of tubular 329 
structures. Additionally, the total area of fluorescence was assessed after automatic segmentation. 330 
Cytotoxicity  331 
Cells were plated on 24-well plates. H2O2 (Sigma-Aldrich) was applied in order to induce 332 
oxidative stress mediated cytotoxicity. We have previously shown that uveal melanoma cell lines 333 
show a cell-line specific susceptibility to oxidative stress [3132].  Cytotoxicity was induced by 334 
applying H2O2 in the respective concentration (92.1: 250 µM, Mel270 and OMM1: 500 µM, OMM2.3 335 
and OMM2.5: 1000 µM). In order to evaluate a potential protective effect of fucoidan, confluent cells 336 
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were treated 30 min prior to oxidative insult with 100 µg/ml fucoidan. Cell viability was assessed 337 
after 24 hours of stimulation with a WST assay. 338 
Whole cell lysate 339 
After treatment of cells as indicated, whole cell lysates were prepared in an NP-40 buffer as 340 
described previously [3733]. In brief, cells were washed with PBS and NP-40 buffer (1% Nonidet® 341 
P40 Substitute, 150 mM NaCl, 50 mM Tris, pH 8.0) was added. The lysates were kept on ice for at 342 
least 30 minutes. Lysates were centrifuged at 13,000 rpm for 15 minutes and the supernatant 343 
harvested. The protein concentration of the supernatant was determined by a BioRad protein assay 344 
(BioRad, München, Germany) with bovine serum albumin (Fluka, Buchs, Switzerland) used as 345 
standard. 346 
Western Blot 347 
Western blot was conducted as described previously with modifications [4952]. In brief, 348 
proteins were separated in an SDS-PAGE, using 12 % acrylamide gels. Gels were blotted on 349 
PVDF-membranes (Carl Roth GmbH, Karlsruhe, Germany) and then blocked in 4 % skim milk in 350 
Tris buffered saline with 0.1 % Tween for 1 hour at room temperature. The blot was treated with the 351 
first antibodies, beta-actin (#4967, 1:1000), Akt (#9272, 1:1000), ERK1/2 (#9102, 1:1000), p-ERK1/2 352 
(#9101, 1:1000) (all Cell-Signaling Technologies, CST, Denver, USA; all rabbit), Bax (sc-20067, 1:1000) 353 
or Bcl-2 (sc-509, 1:1000) (all Santa Cruz, Heidelberg, Germany, all mouse), respectively, in 2% skim 354 
milk in Tris buffered saline with 0.1% Tween overnight at 4°C. After washing the blot, it was 355 
incubated with appropriate secondary antibody (anti-rabbit (#7074) or anti-mouse (#7076) IgG, 356 
HRP-linked antibody (all Cell-Signaling)) in 2% skim milk in Tris-buffered saline with 0.1% Tween 357 
(Merck, Darmstadt, Germany). Following the final wash, the blot was incubated with Immobilon 358 
chemiluminscence reagent (Merck), and the signal was detected with MF-ChemiBis 1.6 (Biostep, 359 
Jahnsdorf, Germany). The density of the bands was evaluated using Total lab software (Biostep) and 360 
the signal was normalized for ß-actin. 361 
Statistics 362 
Statistical analysis was performed with MS-Excel. Means ± standard deviation (sd) was 363 
calculated for at least 3 independent sets of experiments. Significant differences between means 364 
were calculated by t-test. A p-value of 0.05 or less was considered significant. 365 
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